
Commentary|Videos|July 10, 2025
How Data Are Defining the Role of Luspatercept in ESA-Naive, Lower-Risk MDS
Author(s)Guillermo Garcia-Manero, MD
Fact checked by: Chris Ryan
Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5

